Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05477875 · ClinicalTrials.gov registry record · Phase 2

Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control

A Phase 2 study of Myopia and Hyperopia, sponsored by University of Florida.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT05477875 is a Phase 2 study of Myopia and Hyperopia that has completed, run by University of Florida. The registered enrollment target is 35 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05477875, a Phase 2 study of Myopia and Hyperopia, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Photorefractive Keratectomy (PRK) is a commonly performed corneal refractive surgery but has significant post-operative pain. Pain medications after PRK are typically opioid-acetaminophen combinations. Alternatives to opioid medication are worth consideration. Patients will receive PRK in each eye sequentially, using the cannabinoid or codeine/acetaminophen for one eye and the other treatment for the fellow eye two weeks later.

Interventions

  • DRUG oral cannabinoid
  • COMBINATION_PRODUCT oral codeine/acetaminophen

Study Locations (1)

Florida

  • University of Florida Oaks Eye Center - Gainesville

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2024-02-01
Est. Completion 2025-01-22
Phase Phase 2

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT05477875

The ClinicalTrials.gov registry entry for NCT05477875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (87% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which oral cannabinoid is the first listed.

NCT05477875 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05477875 about?

NCT05477875 is a clinical study titled "Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control". Photorefractive Keratectomy (PRK) is a commonly performed corneal refractive surgery but has significant post-operative pain. Pain medications after PRK are typically opioid-acetaminophen combinations. Alternatives to opioid medication are worth consideration. Patients will receive PRK in each eye s...

What is the current status of trial NCT05477875?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-02-01. Estimated completion is 2025-01-22.

What conditions does trial NCT05477875 study?

This clinical trial studies the following conditions: Myopia, Hyperopia, Photorefractive Keratectomy.

What interventions are being tested in trial NCT05477875?

The interventions under investigation include: oral cannabinoid (DRUG), oral codeine/acetaminophen (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05477875?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05477875 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.